Pemdrax 500 Injection contains Pemetrexed 500mg, a potent antineoplastic chemotherapy agent indicated for the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It plays a vital role in controlling tumor progression and improving treatment outcomes in advanced oncology care.
Pemetrexed acts by inhibiting multiple folate-dependent enzymes required for DNA and RNA synthesis in cancer cells, thereby suppressing cell division and inducing apoptosis. Its injectable formulation ensures precise dosing under supervised oncology protocols.
For distributors and healthcare suppliers, Pemdrax 500 Injection is a critical oncology therapy product, widely utilized in tertiary care hospitals, cancer specialty centers, and oncology clinics. The increasing global burden of lung cancer supports sustained demand in the oncology segment.
Adding Pemdrax 500 Injection to your oncology and anticancer therapy segment creates strong opportunities in hospital supply networks, specialty cancer institutions, export markets, and third-party manufacturing. Its proven clinical relevance, prescriber confidence, and essential role in chemotherapy regimens make it a valuable pharmaceutical offering.